Monoclonal antibody · Antagonist of pro-myostatin (MSTN) · developed by Scholar Rock
Apitegromab is a fully human IgG4 monoclonal antibody that binds to pro- and latent myostatin, inhibiting activation of this negative regulator of muscle growth and strength.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05626855 | Phase 3 | Spinal Muscular Atrophy | Active not recruiting | SRRK |
| NCT03921528 | Phase 2 | Spinal Muscular Atrophy | Completed | SRRK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Anti-myostatinAtrophyMuscular AtrophyMuscular Atrophy, SpinalNeuromuscular DiseasesNeuromuscular ManifestationsSMASpinal Muscular AtrophySpinal Muscular Atrophy Type 2Spinal Muscular Atrophy Type 3
Updated Oct 3, 2026. Something wrong or missing? Report it on the SRRK page.
See SRRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRRK catalysts and pipeline →